NCT03145831终止3 期
An Open-Label, Long-Term Safety Study of Long-acting Human Growth Hormone Somavaratan (VRS-317) in Japanese Children With Growth Hormone Deficiency
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 终止
- 入组人数
- 21
- 试验地点
- 1
- 主要终点
- Adverse Events
研究概览
简要总结
This study is a multi-center, open-label safety study assessing long-term somavaratan administration.
详细描述
This study is a multi-center, open-label safety study assessing long-term somavaratan administration. It is open to subjects completing a somavaratan Japanese Phase 2/3 study (Protocol J14VR5) in children with growth hormone deficiency (GHD), as well as approximately 20 new children currently receiving daily rhGH therapy for GHD (switch subjects). For switch subjects, the first dose of somavaratan will be administered approximately 48 hours after the last dose of the daily rhGH. All subjects will receive somavaratan 3.5mg/kg twice-monthly. The study will be conducted at approximately 40 medical institutions in Japan.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 3 Years 至 —（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Chronological Age ≥ 3.0 years.
- •Pre-pubertal status: Absent breast development in girls, testicular volume < 4.0 mL in boys.
- •Subjects with GHD (diagnosed according to the current diagnostic guidelines) who are receiving treatment with daily rhGH.
- •Normal thyroid function at screening visit in subjects not being treated for hypothyroidism. Subjects requiring thyroxine replacement must be considered adequately treated by the PI and Medical Monitor.
- •Normal adrenal function (morning cortisol and/or local stimulation test) at screening visit or within 6 months of the screening visit, in subjects not being treated for adrenal insufficiency. Subjects with adrenal insufficiency must receive glucocorticoid treatment for a minimum of 4 weeks before study drug administration.
- •Pathology relating to cause of GHD must be stable for at least 6 months prior to screening.
- •Willingness to discontinue daily rhGH therapy.
- •Legally authorized representatives must be willing and able to give informed consent
排除标准
- •Prior (in the last 12 months) or concomitant treatment with a growth promoting agent other than rhGH [e.g., IGF-I, GH releasing hormone (GHRH), sex steroids (except when used as primer for GH stimulation test), aromatase inhibitors and/or GnRH agonist].
- •Current significant disease (e.g., diabetes, cystic fibrosis, renal insufficiency). In all cases of concurrent disease, screening must be approved in writing by the medical monitor.
- •Chromosomal aneuploidy, significant gene mutations (other than those that cause GHD) or confirmed diagnosis of a named syndrome (e.g., Russell Silver, Prader Willi, Turner, etc.).
- •Birth weight and/or birth length less than 5th percentile for gestational age using local gestational age growth charts.
- •Prolonged daily (> 14 days) use of anti-inflammatory doses of oral glucocorticoids.
- •Prior history of malignancy.
- •Treatment with an investigational drug in the 30 days prior to screening.
- •Known allergy to constituents of the study drug formulation.
- •Ocular findings suggestive of increased intracranial pressure and/or retinopathy at screening.
- •Significant spinal abnormalities including scoliosis, kyphosis, Chiari malformation, and spina bifida variants.
- •Significant abnormality in screening laboratory studies (as assessed by PI and medical monitor).
- •Current social conditions which would prevent completion of study activities (e.g., planned family move to a distant location).
- •History of pancreatitis or undiagnosed chronic abdominal pain.
- •History of spinal or total body irradiation.
- •Presence of other pituitary hormone deficiencies that are not properly treated.
- •Unwillingness to provide consent for participation in all trial activities
研究组 & 干预措施
Somavaratan
Experimental
fusion protein, subcutaneous bolus injection, 3.5 mg/kg twice monthly
干预措施: Somavaratan (Drug)
结局指标
主要结局
Adverse Events
时间窗: 12 months
Incidence and severity of adverse events
次要结局
- Height velocity(12 months)
- IGF-I expression(12 months)
- Immunogenicity(12 months)
研究者
研究点 (1)
Loading locations...
相似试验
终止
2 期
Versartis Long-Term Safety Study of SomavaratanPediatric Growth Hormone DeficiencyNCT02068521Versartis Inc.385
终止
2 期
Open-label Extension Study to Evaluate the Safety of Long-term Twice-monthly Administration of Somavaratan in Adult Growth Hormone Deficiency (AGHD)Adult Growth Hormone Deficiency (AGHD)NCT02719990Versartis Inc.36
已完成
3 期
A Long-term, Safety, Tolerability, and Efficacy Study of Retigabine Immediate-release (IR) in Asian Adults With Partial Onset SeizuresEpilepsyNCT01777139GlaxoSmithKline30
已完成
3 期
Long Term Safety Study of PlecanatideIrritable Bowel SyndromeNCT02706483Bausch Health Americas, Inc.2,272
已完成
3 期
Open-label Extension (OLE) Study to Assess Safety and Efficacy of EvolocumabHypercholesterolemiaNCT02304484Amgen770